LambdaVision and Vast Sign MOU to Advance Space-Based Manufacturing of Protein-Based Artificial Retina on Commercial Space Stations

June 28, 2026

Business Wire USA

Overview

LambdaVision has signed a Memorandum of Understanding (MOU) with Vast to support research and manufacturing activities on Vast’s Haven-1 and future commercial space stations. LambdaVision has demonstrated, through nine International Space Station (ISS) missions, that microgravity can improve the manufacturing of multi-layered protein thin films for protein-based artificial retinas. This partnership will expand its deployment into commercial Low Earth Orbit (LEO) and aims to accelerate advancements in stem cell science, regenerative medicine, bioprinting, and protein pharmaceutical crystallization in microgravity.

In Depth

Key Findings

Space manufacturing company LambdaVision has signed a Memorandum of Understanding (MOU) with Vast, agreeing to support research and manufacturing activities on Vast’s commercial space station Haven-1 and future orbital facilities. This strategic partnership is set to accelerate the deployment of LambdaVision’s technology for manufacturing multi-layered protein thin films for protein-based artificial retinas in a microgravity environment into commercial Low Earth Orbit (LEO), a capability demonstrated across nine International Space Station (ISS) missions. This represents a significant milestone in space-based biopharmaceutical manufacturing.

Technical and Clinical Details

LambdaVision is developing functional artificial retinas using photoreceptive proteins like rhodopsin. The microgravity environment allows for the manufacturing of uniform, defect-free multi-layered thin films, a process hindered by convection and sedimentation effects on Earth. Across nine ISS missions, the company has demonstrated that microgravity improves the orientation, density, and uniformity of protein layers, leading to enhanced performance of the artificial retina. Vast’s Haven-1 and future commercial space stations will provide a stable platform to scale these technologies from research to commercial production. This partnership will particularly foster technological advancements in the following areas:

Stem Cell Science: Researching the effects of microgravity on stem cell proliferation and differentiation, exploring applications in regenerative medicine.
Regenerative Medicine: Developing new approaches to repair damaged tissues and organs.
Bioprinting: Optimizing 3D printing techniques for complex biological tissues and organs in microgravity.
Protein Pharmaceutical Crystallization: Pursuing the generation of higher purity and more stable protein crystals to contribute to new drug development.

These technologies are directly applicable to both maintaining astronaut health and improving therapies for patients on Earth.

Background and Industry Context

The advent of commercial space stations is dramatically expanding the possibilities for in-orbit research, development, and manufacturing. Companies like Vast aim to utilize the unique microgravity environment to produce high-value products such as pharmaceuticals, regenerative medicine products, and advanced materials. LambdaVision’s artificial retina project is a promising example of how space manufacturing can provide concrete medical solutions, offering new hope to patients suffering from blinding diseases like age-related macular degeneration. This partnership is set to accelerate the growth of the healthcare sector within the space economy and contribute to the formation of an ecosystem with other space manufacturing companies like Varda Space Industries.

Strategic Significance and Outlook

The LambdaVision-Vast partnership is a critical step towards the commercial production of protein-based artificial retinas, with the potential to benefit millions of visually impaired patients. Expanding manufacturing capabilities in commercial Low Earth Orbit will shorten drug development cycles and enable more medical researchers to leverage the benefits of space. This collaboration clearly illustrates a future where space is not just a place for exploration but an innovative manufacturing hub addressing Earth’s most pressing medical needs. In the future, these space manufacturing technologies are expected to be integrated into Earth’s medical infrastructure, becoming a source for new therapeutic interventions.

Source: https://www.businesswire.com/news/home/20260624883923/en/LambdaVision-and-Vast-Sign-Agreement-to-Advance-Space-Based-Manufacturing-of-Protein-Based-Artificial-Retina-and-Microgravity-Bioprocesses

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.